首页 > 市场调查报告书 > 製药

生物製剂

蛋白质疗法市场规模、份额和成长分析（按类型、应用、最终用户、功能和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1902990

蛋白质疗法市场规模、份额和成长分析（按类型、应用、最终用户、功能和地区划分）—产业预测（2026-2033 年）

Protein Therapeutics Market Size, Share, and Growth Analysis, By Type (Monoclonal Antibodies, Insulin), By Application (Metabolic Disorders, Cancer), By End User, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球蛋白质疗法市场规模将达到 3,722 亿美元，从 2025 年的 3,983.6 亿美元成长到 2033 年的 6,860 亿美元，在预测期（2026-2033 年）内复合年增长率为 7.03%。

对多种疾病有效治疗方法的日益增长的需求正显着推动蛋白质疗法市场的发展。随着糖尿病、自体免疫疾病和癌症等慢性疾病日益普遍（主要受人口老化影响），对蛋白质治疗方法的需求也随之增加。与传统的小分子药物不同，生物製药因其疗效较佳、副作用较少、特异性较高而备受青睐。单株抗体在蛋白质工程和生物技术进步的推动下，引领着蛋白质疗法领域的发展。这种创新环境正促进下一代生物製剂的研发，包括融合蛋白和双特异性抗体。慈善机构和政府的奖励推动了罕见疾病研究的进展，而随着原研究生物製剂专利的到期，生物相似药的推出进一步推动了市场的发展，改善了不同患者群体获得治疗的机会。

蛋白质疗法市场驱动因素

全球蛋白质疗法市场的主要驱动因素之一是癌症、糖尿病和自体免疫疾病等慢性疾病的日益普遍。随着这些疾病负担的加重，人们对创新有效的治疗方案（包括蛋白质治疗方法）的需求也日益增长。这些疗法具有标靶作用机制，与传统疗法相比，能够带来更好的患者疗效和更少的副作用。此外，生物技术和基因组学的进步正在推动新型蛋白质疗法的研发，进一步促进市场成长，并吸引製药公司和研究机构的大量投资。

蛋白质疗法市场面临的限制

全球蛋白质疗法市场的主要限制因素之一是蛋白质药物研发和生产过程的高成本。蛋白质工程的复杂性，加上严格的监管核准要求，会导致漫长而昂贵的研发阶段。此外，生物製药的生产通常需要专门的设施和设备，进一步推高了成本。这些经济壁垒会限制中小型生物技术公司的进入，扼杀创新，最终影响市场供应和患者获得新型治疗方案的机会。因此，高成本可能会阻碍整个市场的成长和蛋白质疗法的广泛应用。

蛋白质疗法市场趋势

蛋白质疗法市场正经历着显着的个人化趋势，这主要源于对根据个体基因和分子特征量身定制的治疗方案日益增长的需求。这种转变不仅提高了治疗效果，还最大限度地减少了副作用，使治疗方案对医疗服务提供者和患者都更具吸引力。随着癌症和自体免疫疾病等疾病的日益普遍，标靶生物製药和先进蛋白质疗法的应用正在加速。这一发展趋势反映了医疗保健领域向精准医疗迈进的更广泛趋势，并刺激了对先进治疗方法研发的创新和投资，这些疗法有望改善患者预后并提高整个医疗保健系统的效率。

Johnson & Johnson（United States）
Roche（Switzerland）
Merck & Co.（United States）
Pfizer（United States）
AbbVie（United States）
Sanofi（France）
AstraZeneca（United Kingdom）
Novartis（Switzerland）
Bristol-Myers Squibb（United States）
Abbott Laboratories（United States）
GlaxoSmithKline（United Kingdom）
Novo Nordisk（Denmark）
Eli Lilly and Company（United States）
Amgen（United States）
Gilead Sciences（United States）
Biogen（United States）
Bayer（Germany）
Takeda Pharmaceutical Company（Japan）
CSL Behring（Australia）
Teva Pharmaceutical Industries（Israel）

结论与建议

简介目录

Product Code: SQMIG35H2238

Protein Therapeutics Market size was valued at USD 372.2 Billion in 2024 and is poised to grow from USD 398.36 Billion in 2025 to USD 686 Billion by 2033, growing at a CAGR of 7.03% during the forecast period (2026-2033).

The rising demand for effective treatments addressing multiple ailments has significantly boosted the protein therapeutics market. As chronic diseases such as diabetes, autoimmune disorders, and cancer become more prevalent, driven largely by an aging population, the need for protein-based therapies intensifies. Unlike traditional small-molecule drugs, biologics offer superior efficacy, reduced side effects, and increased specificity, resulting in their growing popularity. Monoclonal antibodies lead the protein therapy segment, supported by advances in protein engineering and biotechnology. This innovative landscape fosters the development of next-generation biologics, including fusion proteins and bispecific antibodies. Charitable initiatives and government incentives are advancing research on rare diseases, while the introduction of biosimilars further evolves the market as patents for original biologics expire, enhancing treatment accessibility for diverse patient populations.

Top-down and bottom-up approaches were used to estimate and validate the size of the Protein Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Protein Therapeutics Market Segments Analysis

Global Protein Therapeutics Market is segmented by Type, Application, End User, Function and region. Based on Type, the market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Human Growth Hormone, Erythropoietin and Interferon. Based on Application, the market is segmented into Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical companies, Healthcare Service Providers, Research Organizations and Academic Research Institutes. Based on Function, the market is segmented into Vaccines, Enzymatic and Regulatory and Protein Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Protein Therapeutics Market

One key market driver for the global protein therapeutics market is the increasing prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders. As the burden of these conditions rises, there is a growing demand for innovative and effective treatment options, including protein-based therapies. These therapeutics offer targeted mechanisms of action, which can lead to improved patient outcomes and reduced side effects compared to traditional treatments. Additionally, advancements in biotechnology and genomics are facilitating the development of novel protein therapeutics, further accelerating market growth and attracting significant investment from both pharmaceutical companies and research institutions.

Restraints in the Protein Therapeutics Market

One significant market restraint for the global protein therapeutics market is the high cost of development and manufacturing processes associated with protein-based drugs. The complexity of protein engineering, coupled with stringent regulatory requirements for approval, can lead to lengthy and expensive research phases. Additionally, the production of biologics often requires specialized facilities and equipment, further inflating costs. These financial barriers can limit the participation of smaller biotech companies and hinder innovations, ultimately affecting market availability and access to new therapeutic options for patients. As a result, high costs can impede overall market growth and adoption of protein therapeutics.

Market Trends of the Protein Therapeutics Market

The protein therapeutics market is experiencing a significant trend towards personalization, fueled by the increasing demand for tailored treatment solutions that align with individual genetic and molecular profiles. This shift not only enhances therapeutic efficacy but also minimizes adverse effects, making treatments more appealing to both healthcare providers and patients. As conditions like cancer and autoimmune diseases become more prevalent, the adoption of targeted biologics and advanced protein therapies is accelerating. This evolution reflects a broader move in healthcare towards precision medicine, driving innovation and investment in the development of sophisticated therapies that promise improved patient outcomes and a more effective healthcare system overall.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Protein Therapeutics Market Size by Type & CAGR (2026-2033)

Market Overview
Monoclonal Antibodies
Insulin
Fusion Protein
Human Growth Hormone
Erythropoietin
Interferon

Global Protein Therapeutics Market Size by Application & CAGR (2026-2033)

Market Overview
Cancer
Metabolic Disorders
Immunologic Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others

Global Protein Therapeutics Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical companies
Healthcare Service Providers
Research Organizations
Academic Research Institutes

Global Protein Therapeutics Market Size by Function & CAGR (2026-2033)

Market Overview
Vaccines
Enzymatic and Regulatory
Protein Diagnostics

Global Protein Therapeutics Market Size & CAGR (2026-2033)

North America (Type, Application, End User, Function)
- US
- Canada
Europe (Type, Application, End User, Function)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, End User, Function)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, End User, Function)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, End User, Function)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments